Promising Activity Reported for Nivolumab in Gynecologic Cancers
Nivolumab, a programmed death (PD)-1 inhibitor, showed promising clinical activity in recurrent or metastatic cervical cancers and provides a promising new approach to treatment.
Diagnosis & Disease Information
Sarcoma: Next-generation Sequencing Has Implications for Diagnosis and Treatment
A retrospective analysis of next-generation sequencing profiles has diagnostic and therapeutic implications for patients with soft-tissue or bone sarcoma.
Personalizing Care for Patients With Sarcoma
The landscape of complex genetic mutations in sarcomas seen through next-generation sequence profiling provides a rationale for a study to match patients to the appropriate therapy.
Endometrial Cancer: Adjuvant Taxane Plus Platinum Agent Does Not Improve Outcomes
A study concluded that adjuvant therapy with a taxane and a platinum agent was not superior over standard therapy for women with high-risk endometrial cancer.
Yoga Improves Sleep Disorders, Fatigue in Patients With Cancer
Improvements in cancer-related fatigue from yoga were linked to improvements in sleep quality and daytime dysfunction.
Toxicity-driven Sunitinib Dosing Improves Outcomes in RCC
Toxicity-driven dosing of sunitinib improved response rates and survival compared with historical standard dosing among patients with metastatic renal cell carcinoma.
Plasma HGF Levels During Treatment Prognostic for Survival in RCC
Patients with a decline in HGF levels had longer overall survival than those with high levels at baseline and at 4 weeks.
Two-to-One Sunitinib Schedule Fails To Reduce Toxicity
A modified dosing schedule of sunitinib did not improve adverse events rates among patients with metastatic renal cell carcinoma.
Pembrolizumab Active in Few Soft Tissue, Bone Sarcoma Subtypes
Pembrolizumab shows antitumor activity in osteosarcoma and undifferentiated pleomorphic sarcoma, but not other types of soft tissue sarcomas.
Cabozantinib Evaluated in Aggressive Endometrial Cancer Subtype
Cabozantinib may have activity in carcinosarcoma and warrants further investigation.
- Loading...
Loading...
Next post in ASCO 2017
Loading... 
Loading...